Shandong Wohua Pharmaceutical Co., Ltd.
Simbolis: 002107.SZ
SHZ
4.82
CNYRinkos kaina šiandien
64.7237
P/E santykis
-0.2255
PEG koeficientas
2.78B
MRK kapitalizacija
- 0.00%
DIV pajamingumas
Shandong Wohua Pharmaceutical Co., Ltd. (002107-SZ) Finansinės ataskaitos
Balansas
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 1553.9 | 401.1 | 278.3 | 326.8 | |||||||||||||||||||||
balance-sheet.row.short-term-investments | 0 | 0 | 0 | 0 | |||||||||||||||||||||
balance-sheet.row.net-receivables | 489.91 | 120.5 | 165.9 | 120.6 | |||||||||||||||||||||
balance-sheet.row.inventory | 580.07 | 149.1 | 146 | 165.9 | |||||||||||||||||||||
balance-sheet.row.other-current-assets | 31.94 | 2.3 | 9 | 7.2 | |||||||||||||||||||||
balance-sheet.row.total-current-assets | 2655.83 | 673 | 599.2 | 620.6 | |||||||||||||||||||||
balance-sheet.row.property-plant-equipment-net | 1542.42 | 383.2 | 409.8 | 447.7 | |||||||||||||||||||||
balance-sheet.row.goodwill | 130.03 | 32.5 | 32.5 | 32.5 | |||||||||||||||||||||
balance-sheet.row.intangible-assets | 144.07 | 36.8 | 36 | 54.8 | |||||||||||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 274.1 | 69.4 | 68.5 | 87.3 | |||||||||||||||||||||
balance-sheet.row.long-term-investments | 73.91 | 18.4 | 19.1 | 0 | |||||||||||||||||||||
balance-sheet.row.tax-assets | 2.8 | 0.7 | 1.2 | 2.8 | |||||||||||||||||||||
balance-sheet.row.other-non-current-assets | 6.43 | 0 | 2.2 | 2.7 | |||||||||||||||||||||
balance-sheet.row.total-non-current-assets | 1899.66 | 471.7 | 500.8 | 540.5 | |||||||||||||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | |||||||||||||||||||||
balance-sheet.row.total-assets | 4555.49 | 1144.7 | 1100 | 1161.1 | |||||||||||||||||||||
balance-sheet.row.account-payables | 223.67 | 52.9 | 45.3 | 26.8 | |||||||||||||||||||||
balance-sheet.row.short-term-debt | 4.7 | 2.7 | 1 | 2.8 | |||||||||||||||||||||
balance-sheet.row.tax-payables | 39.43 | 3.1 | 31.3 | 20.9 | |||||||||||||||||||||
balance-sheet.row.long-term-debt-total | -17.39 | -17.9 | 0.4 | 0.1 | |||||||||||||||||||||
Deferred Revenue Non Current | 72.77 | 17.9 | 20.7 | 23.8 | |||||||||||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 17.38 | - | - | - | |||||||||||||||||||||
balance-sheet.row.other-current-liab | 762.54 | 226.7 | 224.7 | 168.5 | |||||||||||||||||||||
balance-sheet.row.total-non-current-liabilities | 75.16 | 5.3 | 26.8 | 28.1 | |||||||||||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | |||||||||||||||||||||
balance-sheet.row.capital-lease-obligations | 1.01 | 0.4 | 0.4 | 0 | |||||||||||||||||||||
balance-sheet.row.total-liab | 1209.2 | 293.3 | 310.2 | 231.8 | |||||||||||||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | |||||||||||||||||||||
balance-sheet.row.common-stock | 2308.84 | 577.2 | 577.2 | 577.2 | |||||||||||||||||||||
balance-sheet.row.retained-earnings | 731.37 | 183.8 | 129.7 | 183.7 | |||||||||||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 167.6 | 44.2 | 39.6 | 59.8 | |||||||||||||||||||||
balance-sheet.row.other-total-stockholders-equity | 0 | 0 | 0 | 0 | |||||||||||||||||||||
balance-sheet.row.total-stockholders-equity | 3207.81 | 805.3 | 746.5 | 820.7 | |||||||||||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 4555.49 | 1144.7 | 1100 | 1161.1 | |||||||||||||||||||||
balance-sheet.row.minority-interest | 120.56 | 28.2 | 43.3 | 108.5 | |||||||||||||||||||||
balance-sheet.row.total-equity | 3328.36 | 833.5 | 789.8 | 929.3 | |||||||||||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 4555.49 | - | - | - | |||||||||||||||||||||
Total Investments | 73.91 | 18.4 | 19.1 | 0 | |||||||||||||||||||||
balance-sheet.row.total-debt | 4.74 | 2.7 | 1.4 | 2.8 | |||||||||||||||||||||
balance-sheet.row.net-debt | -1549.16 | -398.4 | -276.9 | -324 |
Pinigų srautų ataskaita
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 42.99 | 58.8 | 89.9 | 161.3 | |||||||||||||||||||||
cash-flows.row.depreciation-and-amortization | -0.12 | 33.2 | 35.3 | 33 | |||||||||||||||||||||
cash-flows.row.deferred-income-tax | 0 | 0.7 | 2.2 | 1.3 | |||||||||||||||||||||
cash-flows.row.stock-based-compensation | 0 | -18.9 | -2.2 | -1.3 | |||||||||||||||||||||
cash-flows.row.change-in-working-capital | 44.96 | 47.6 | 54.9 | -14 | |||||||||||||||||||||
cash-flows.row.account-receivables | 50.32 | 50.3 | -40.8 | 63.3 | |||||||||||||||||||||
cash-flows.row.inventory | -5.36 | -5.4 | 15.5 | -53.8 | |||||||||||||||||||||
cash-flows.row.account-payables | 0 | 2.6 | 78.1 | -24.8 | |||||||||||||||||||||
cash-flows.row.other-working-capital | 0 | 0 | 2.2 | 1.3 | |||||||||||||||||||||
cash-flows.row.other-non-cash-items | 64.7 | 7.8 | 5.1 | 19.8 | |||||||||||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 152.53 | 0 | 0 | 0 | |||||||||||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | -2.21 | -2.7 | -6.8 | -19.1 | |||||||||||||||||||||
cash-flows.row.acquisitions-net | 0.06 | 0.1 | 1.2 | 0 | |||||||||||||||||||||
cash-flows.row.purchases-of-investments | 0 | 0 | 0 | 0 | |||||||||||||||||||||
cash-flows.row.sales-maturities-of-investments | 0 | 0 | 0 | 0 | |||||||||||||||||||||
cash-flows.row.other-investing-activites | 0.06 | 0 | 0 | 0 | |||||||||||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | -2.15 | -2.6 | -5.6 | -19.1 | |||||||||||||||||||||
cash-flows.row.debt-repayment | 0 | 0 | -0.3 | -188.8 | |||||||||||||||||||||
cash-flows.row.common-stock-issued | 0 | 0 | 0 | 0 | |||||||||||||||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | 0 | 0 | |||||||||||||||||||||
cash-flows.row.dividends-paid | 0 | 0 | -150.1 | -154.9 | |||||||||||||||||||||
cash-flows.row.other-financing-activites | -3.55 | -3.6 | -79 | -188.8 | |||||||||||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | -3.55 | -3.6 | -229.3 | -343.7 | |||||||||||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | -0.14 | -0.3 | 0 | 0 | |||||||||||||||||||||
cash-flows.row.net-change-in-cash | 147.9 | 122.8 | -49.7 | -162.6 | |||||||||||||||||||||
cash-flows.row.cash-at-end-of-period | 1551.56 | 401.1 | 276.5 | 326.2 | |||||||||||||||||||||
cash-flows.row.cash-at-beginning-of-period | 1403.67 | 278.3 | 326.2 | 488.9 | |||||||||||||||||||||
cash-flows.row.operating-cash-flow | 152.53 | 129.2 | 185.3 | 200.1 | |||||||||||||||||||||
cash-flows.row.capital-expenditure | -2.21 | -2.7 | -6.8 | -19.1 | |||||||||||||||||||||
cash-flows.row.free-cash-flow | 150.32 | 126.5 | 178.5 | 181 |
Pajamų ataskaitos eilutė
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 882.86 | 894.3 | 1014.8 | 942.7 | |||||||||||||||||||||
income-statement-row.row.cost-of-revenue | 235.14 | 241.4 | 250.9 | 212.4 | |||||||||||||||||||||
income-statement-row.row.gross-profit | 647.73 | 652.9 | 763.9 | 730.3 | |||||||||||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | |||||||||||||||||||||
income-statement-row.row.research-development | 37.89 | - | - | - | |||||||||||||||||||||
income-statement-row.row.selling-general-administrative | 19.49 | - | - | - | |||||||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 491.95 | - | - | - | |||||||||||||||||||||
income-statement-row.row.other-expenses | 0.2 | -2.3 | 63 | 41.9 | |||||||||||||||||||||
income-statement-row.row.operating-expenses | 613.64 | 606.5 | 651.5 | 523.4 | |||||||||||||||||||||
income-statement-row.row.cost-and-expenses | 848.78 | 848 | 902.4 | 735.7 | |||||||||||||||||||||
income-statement-row.row.interest-income | 4.85 | 5.2 | 4.7 | 6.8 | |||||||||||||||||||||
income-statement-row.row.interest-expense | 0.03 | 0 | 0 | 4.7 | |||||||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 491.95 | - | - | - | |||||||||||||||||||||
income-statement-row.row.total-other-income-expensenet | 5.22 | 8.3 | -1.5 | -2.7 | |||||||||||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | |||||||||||||||||||||
income-statement-row.row.other-operating-expenses | 0.2 | -2.3 | 63 | 41.9 | |||||||||||||||||||||
income-statement-row.row.total-operating-expenses | 5.22 | 8.3 | -1.5 | -2.7 | |||||||||||||||||||||
income-statement-row.row.interest-expense | 0.03 | 0 | 0 | 4.7 | |||||||||||||||||||||
income-statement-row.row.depreciation-and-amortization | 18.56 | 33.2 | 38.5 | 50.1 | |||||||||||||||||||||
income-statement-row.row.ebitda-caps | 48.25 | - | - | - | |||||||||||||||||||||
income-statement-row.row.operating-income | 34.94 | 46.3 | 112.3 | 192.7 | |||||||||||||||||||||
income-statement-row.row.income-before-tax | 40.17 | 54.6 | 110.8 | 190 | |||||||||||||||||||||
income-statement-row.row.income-tax-expense | 7.01 | 8 | 20.9 | 28.6 | |||||||||||||||||||||
income-statement-row.row.net-income | 42.99 | 58.8 | 107.4 | 163.4 |
Dažnai užduodami klausimai
Kas yra Shandong Wohua Pharmaceutical Co., Ltd. (002107.SZ) bendras turtas?
Shandong Wohua Pharmaceutical Co., Ltd. (002107.SZ) bendras turtas yra 1144706388.000.
Kokios yra įmonės metinės pajamos?
Metinės pajamos yra 401753358.000.
Kokia yra įmonės pelno marža?
Įmonės pelno marža yra 0.734.
Koks yra įmonės laisvųjų pinigų srautas?
Laisvųjų pinigų srautas yra 0.260.
Kokia yra įmonės grynojo pelno marža?
Grynojo pelno marža yra 0.049.
Kokios yra bendros įmonės pajamos?
Bendrosios pajamos yra 0.040.
Kas yra Shandong Wohua Pharmaceutical Co., Ltd. (002107.SZ) grynasis pelnas (grynosios pajamos)?
Grynasis pelnas (grynosios pajamos) yra 58767086.000.
Kokia yra bendra įmonės skola?
Bendra skola yra 2727141.000.
Koks yra veiklos sąnaudų skaičius?
Veiklos sąnaudos yra 606549582.000.
Koks yra įmonės grynųjų pinigų skaičius?
Įmonės grynieji pinigai yra 456686925.000.